This was the stock's second consecutive day of losses.

CAMBRIDGE, Mass., March 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights ...

"It’s as much of the marquee high-value transactions as it is the aggregation of what we call our bread and butter, and it’s ...

BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to ...

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

Analysts have taken a lukewarm stance on Bristol-Myers Squibb, dishing out a mixed bag of stock ratings that’s less “fireworks” and more “flickering candle.” Out of nineteen brokerages, eleven slapped ...

Bristol Myers Squibb has been a strong performer in the six months, rising over 23% in that time. Investors desiring to ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

Research in mice identifies protein responsible for regulating gut movement in response to pressure, exercise, and ...

But what it does have is its critical role—albeit underrated—as a biotech hub. Competing with South San Francisco and Boston, ...

Lexicon Pharmaceuticals and Bristol-Myers Squibb, though both in pharma, are leagues apart in scale, profitability, and risk.

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...